Medical News

RSS

A weight-loss drug eased knee arthritis pain in two major trials

Retatrutide effectively alleviates knee pain and enhances mobility in obese osteoarthritis patients, but long-term safety and joint health remain uncertain.

10 Nov 2026

Could a common diabetes drug help prevent long COVID?

Metformin use soon after COVID-19 infection is associated with a 53% reduction in long COVID or death risk, reinforcing previous clinical findings.

10 Nov 2026

New $46M grant allows the University of Oxford and Boston Children’s Hospital to lead Genetic Medicines Hub within ARIA ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

10 Nov 2026

Could Ozempic and Wegovy affect unborn babies?

They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds.

10 Nov 2026

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

Lab Thread Ltd, a UK-based life science software company, today announced the launch of a new Model Context Protocol (MCP) server that lets scientists connect their own AI assistants directly to their laboratory data.

From Lab Thread 10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

European commission approves label expansion of Pepaxti to third-line treatment

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen).

From Oncopeptides AB (publ) 10 Nov 2026

Why are some patients lying to their doctors to get antibiotics?

A study finds 28% of adults misrepresent symptoms to secure antibiotics, highlighting risks for antimicrobial resistance and the need for better communication.

10 Nov 2026

Crystal Pharmatech completes ELDICO ED-1 installation; Dedicated MicroED now in routine service

Crystal Pharmatech, a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulation development and manufacturing for small-molecule drugs, today announced that installation of the ELDICO ED-1 electron diffractometer at its Suzhou, China R&D center is complete.

From ELDICO Scientific AG 10 Nov 2026

‘Fossil record’ in stored blood samples lets scientists trace leukemia back decades before diagnosis

Scientists have reconstructed how acute myeloid leukemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases the first cancer-driving mutation had been acquired before the age of 20—more than 50 years before diagnosis.

10 Nov 2026

Your Instagram photos may reveal more about loneliness than you think

Researchers analyzing Instagram data from 415 US college students found that photographs, language, and online activity provided moderately useful indicators of subjective loneliness but were less informative about social isolation. Social loneliness was associated with lower interpersonal engagement, while emotional loneliness was linked to negative language, sad or angry facial expressions in profile photographs, and late-night posting.

9 Nov 2026

Drinking 2–3 cups of coffee a day? A study of 495,000 adults links it to lower AF risk

In a prospective study of 495,269 UK Biobank participants followed for approximately 13 years, researchers found that coffee consumption was associated with a 7% to 11% lower risk of atrial fibrillation (AF), with the strongest association observed at 2–3 cups daily. Tea consumption showed a more modest and less consistent association, with the authors reporting a 5% lower AF risk at 2–3 cups daily, although the observational findings cannot establish causation.

9 Nov 2026

BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

BioUK Ltd., the not-for-profit membership organization focused on catalyzing success in UK life sciences, today announced that it has acquired certain key assets of SEHTA (Science and Engineering Health Technologies Alliance) through an asset purchase agreement.

From BioUK 9 Nov 2026

A child's sex may change how early sugar intake relates to body fat

A longitudinal study of 130 mother-child pairs found that added sugar intake during pregnancy was more strongly associated with body fat in girls, whereas exposure during infancy was more strongly associated with adiposity in boys at age two. The findings, based largely on a smaller group of 42 children with usable body-composition scans, are preliminary and do not establish a causal relationship.

9 Nov 2026

Late night eating and sleep habits damage gut health, increase metabolic disease risk

A new study led by UTHealth Houston identified a link between late-night eating and sleeping habits, gut health, and metabolic disease, offering new insights into why some individuals with obesity may face risk of inflammation and related health problems.

9 Nov 2026

Most eligible teens miss out on advanced obesity treatments

Despite the arrival of powerful new anti-obesity medications and growing evidence supporting weight-loss surgery for adolescents, the vast majority of eligible teens are receiving neither treatment, according to a new study from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Pediatrics.

9 Nov 2026

Medical News

A weight-loss drug eased knee arthritis pain in two major trials

Could a common diabetes drug help prevent long COVID?

New $46M grant allows the University of Oxford and Boston Children’s Hospital to lead Genetic Medicines Hub within ARIA ecosystem

Could Ozempic and Wegovy affect unborn babies?

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

European commission approves label expansion of Pepaxti to third-line treatment

Why are some patients lying to their doctors to get antibiotics?

Crystal Pharmatech completes ELDICO ED-1 installation; Dedicated MicroED now in routine service

‘Fossil record’ in stored blood samples lets scientists trace leukemia back decades before diagnosis

Your Instagram photos may reveal more about loneliness than you think

Drinking 2–3 cups of coffee a day? A study of 495,000 adults links it to lower AF risk

BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

A child's sex may change how early sugar intake relates to body fat

Late night eating and sleep habits damage gut health, increase metabolic disease risk

Most eligible teens miss out on advanced obesity treatments

Complex procedure offers relief for children with chronic pancreatitis

DNA methylation patterns predict treatment response in MDS patients

UCLA study identifies lipid imbalance as pulmonary fibrosis trigger

Rutgers receives grant to explore drug overdose trends among youth

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News